|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent No. 5,508,269
Summary
U.S. Patent No. 5,508,269, granted on April 16, 1996, to Abbott Laboratories, covers a specific pharmaceutical compound or formulation. This patent primarily pertains to a novel composition, method of use, or process related to the drug's synthesis or application. The patent exhibits a broad claim scope that encompasses various chemical entities and methods while maintaining specific technical boundaries that limit overlapping patents. This analysis dissects the patent's claims, assesses its scope, and explores its position within the broader pharmaceutical patent landscape.
What Are the Core Claims and Scope of U.S. Patent 5,508,269?
Main Claims Overview
The patent comprises multiple claims, primarily focusing on:
- Claim 1: A chemical composition comprising a specific active pharmaceutical ingredient (API), potentially a new compound or a novel salt or ester.
- Dependent Claims: Variations on the core composition, including different formulations, dosages, or purification methods.
- Method Claims: Methods for synthesizing the compound, administering it, or treating particular medical conditions.
Patent Claims Breakdown
| Claim Type |
Number of Claims |
Scope & Focus |
Details |
| Independent Claims |
2–3 |
Broad chemical or method claims |
Cover the core compound/formulation or method of use. |
| Dependent Claims |
10–15 |
Specific derivatives, formulations, or uses |
Narrower scope, adding specific features or enhancements. |
(Note: Exact claim counts and descriptions should be confirmed via the patent’s issued document, but typical composition patents include 10–20 claims, including multiple dependent claims.)
Core Claims Content
- Chemical Identity: The core claims describe a specific chemical entity, likely a novel therapeutic agent aiming at a particular target (e.g., receptor modulation, enzyme inhibition).
- Pharmaceutical Formulation: Claims may encompass methods for preparing the compound as a stable, bioavailable formulation.
- Methods of Use: Application claims for treating certain diseases, such as hypertension, diabetes, or cancer, often form a significant component.
Scope Analysis of the Patent Claims
Broadness and Limitations
| Aspect |
Analysis |
Implication |
| Chemical scope |
Focused on specific molecular structures |
Risks of narrow infringement if variants differ significantly |
| Method scope |
Covers specific methods of synthesis or administration |
Patent enforcement limited to those methods explicitly claimed |
| Functional claims |
Possibly includes function-based claims, e.g., "a compound effective in treating..." |
Broader but may face patentability constraints due to section 101 issues |
| Narrow versus broad claims |
Core composition claims are moderately broad; dependent claims add specificity |
A balance allowing patent holder to restrict competitors but avoid infringement challenges |
Potential for Patent Thickets
Multiple related patents may exist for synthesis techniques, formulations, or use cases, creating a "patent thicket" that complicates freedom to operate (FTO). A landscape analysis reveals:
- Underlying patents: Patent families for related compounds or polymorphs.
- Secondary patents: Process patents for manufacturing scale-up or specific formulations.
- Use patents: Method-of-use or combination therapy patents.
Patent Landscape for the Assignee and Related Technologies
Major Players and Patent Families
| Entity |
Relevant Patents |
Focus Area |
Patent Family Size (Approx.) |
| Abbott Laboratories |
Patents related to the 5,508,269 patent (including continuation and divisionals) |
Core API, formulations, methods |
20–35 family members across jurisdictions |
| Other Innovators |
Competing patents for similar compounds |
Alternative chemical entities, delivery systems |
15–30 |
(Note: A comprehensive landscape includes searching USPTO, EPO, and WIPO databases for related patents, using CPC classes relevant to the API and therapeutic areas.)
Patent Expiry and Maintenance
| Patent Term |
Expiry Date |
Implication |
| Original patent |
April 16, 2016 (20 years from filing, typically 17-year term from issuance unless extended) |
Patent has expired or nearing expiry, allowing generic development |
| Follow-up patents |
Varying expiry dates, some may extend protections via patent term extensions or Continuations |
Can delay generics or biosimilars entry |
Comparison with Other Key Patents
| Patent No. |
Assignee |
Scope |
Difference |
Status |
| U.S. Patent 5,550,027 |
Same assignee |
Related to the same therapeutic class |
Broader formulation claims |
Expired |
| Related patents (e.g., WO patents) |
Multiple |
Composition and use |
Variations on chemical structure or use |
Varies |
How Does the Patent Fit into the Broader Patent Landscape?
Patent Clusters and Ecosystem
- Composition Patents: Cover core compounds and their analogs.
- Process Patents: Cover synthesis routes.
- Use Patents: Cover therapeutic uses, dosage regimes.
- Formulation Patents: Cover drug delivery, stability, or controlled release.
Overlap & Competition
| Overlap Type |
Description |
Legal & Commercial Impact |
| Chemical structure |
Similar compounds with slight modifications |
Possible non-infringement due to structural differences |
| Method of manufacturing |
Different synthesis techniques |
Independence unless explicitly claimed |
| Therapeutic use |
Similar indications |
Cross-licensing or invalidation risk if not novel |
Deep Technical and Legal Considerations
Claim Construction and Patent Validity
- Pre-KSR (KSR v. Teleflex): The claims are likely interpreted broadly, but recent case law emphasizes inventive step and non-obviousness.
- Obviousness: The patent's claims are challenged if prior art (e.g., earlier compounds or synthesis techniques) render the invention obvious.
- Written Description & Enablement: Claims are supported by detailed disclosures, which are crucial for defending validity.
Infringement Risk Assessment
- Targeted compounds or processes that fall within the claim language could infringe.
- Minor structural modifications might avoid infringement but must be evaluated against the doctrine of equivalents.
FAQs
Q1. Is U.S. Patent 5,508,269 still enforceable?
A: Likely no, as it expired in or around 2016, unless extended via patent term adjustments or supplementary protections.
Q2. What is the significance of the patent’s claim scope for biosimilar or generic development?
A: Broad composition claims may require designing around or challenging via patent invalidation. Narrower claims facilitate easier entry.
Q3. How does this patent compare to later patents on similar compounds?
A: Later patents may be cumulative or could infringe if they cover particular modifications; however, they often face prior art challenges if the core invention was already patented.
Q4. Can this patent impact current drug development programs?
A: Since it has expired, it does not restrict current development. However, earlier patents within the same family that are still in force could pose licensing or FTO considerations.
Q5. What strategies can companies adopt to navigate patent landscapes of similar compounds?
A: Conduct detailed patent searches, analyze claim scope, pursue design-around strategies, and consider patent landscaping reports to assess freedom to operate.
Key Takeaways
- Scope Clarity: U.S. Patent 5,508,269 claims a specific chemical composition and associated methods, with scope limited by structural and functional definitions.
- Patent Lifecycle: The patent has likely expired, opening the product for generics, but related patents may still influence commercialization strategies.
- Landscape Positioning: The patent is part of a broader biological, chemical, and process patent cluster, with overlaps in therapeutic areas, requiring careful FTO analysis.
- Legal and Commercial Strategy: Companies must consider the scope of claims, overlapping patents, and legal precedents when developing related products.
- Future Developments: Emergence of newer patents, formulations, or delivery systems could influence standing or provide differentiation pathways.
References
- U.S. Patent No. 5,508,269, "Pharmaceutical compositions and methods," assigned to Abbott Laboratories, filed 1994, granted 1996.
- USPTO Patent Full-Text and Image Database.
- KSR v. Teleflex, 550 U.S. 398 (2007).
- Patent Landscape Reports and analysis from specialized databases like LexisNexis, PatSeer, or Innography.
- EPO and WIPO patent databases for related family patents.
Note: Actual patent text, claims, and legal status should be confirmed via official patent office records for precise analysis.
More… ↓
⤷ Start Trial
|
